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E-mail address: shorningb@cf.ac.uk (B.Y. ShorningRecent developments have placed the serine/threonine kinase LKB1 on the crossroads linking
energy metabolism, cell structure and cancer progression and that its deletion can affect tumorigen-
esis, metastasis, cell adhesion and polarity. LKB1 can regulate a host of different functions which all
have potential to impact upon the initiation and progression of neoplastic disease. To understand
the phenotypic consequences of LKB1 loss in a range of different settings, a number of animal mod-
els of loss of function have been generated and analyzed. In this review we summarize recent data
generated from a range of these models, which reveal clear tissue speciﬁc differences in LKB1 func-
tion in vivo and in the consequences of its loss.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Background
LKB1/STK11 is a serine/threonine kinase that controls diverse
cellular processes through phosphorylation of a conserved threo-
nine residue in a family of kinases [1,2]. As a consequence of the
broad range of LKB1 substrates, LKB1 potentially impacts on a very
wide range of cellular processes. Key amongst these functions is
the activation of AMPK kinase when cellular energy levels are de-
pleted to restore the ATP/AMP ratio through promotion of ATP pro-
duction and blocking of its consumption [2]. However, LKB1 has
been implicated in many other processes relevant to tumour initi-
ation and progression. Hence, in concert with AMPK, LKB1 restricts
cell growth by activation of the TSC1/TSC2 complex and subse-
quent blocking of Rheb and mTOR [3], a pathway which is also sup-
pressed by AMPK via phosphorylation of the regulatory-associated
protein of mTOR (raptor) [4]. AMPK itself not only affects metabo-
lism and cell growth but also stabilizes contacts between cells by
tight junction assembly [5]. LKB1 has also been implicated in con-
trolling cell polarity, mainly through the targeting of four members
of the MARK (microtubule afﬁnity-regulating kinases) and SAD
(BRSK) families [6,7]. Furthermore, LKB1 has been shown to inﬂu-
ence cell adhesion, cell death, detachment and invasion, for exam-
ple though regulation of NUAK1 kinase activity, which is important
for cytoskeletal motor protein regulation [8], and by regulation of
SIK1-dependent anoikis [9].
LKB1 normally functions inside a large protein complex that
also includes STRADa and MO25 [10,11]. In this structure,chemical Societies. Published by E
).MO25 stabilizes the complex and STRADa promotes the active
conformation of LKB1, stimulating catalytic activity and facilitating
LKB1 export from the nucleus to the cytoplasm [12,13]. Interest-
ingly, LKB1 has a dual nuclear-cytoplasmic function and it is inac-
tive when its localization restricted to the nucleus only [14].
Mammalian LKB1 is highly homologous to its counterparts in
Drosophila, Xenopus (XEEK1) and Caenorhabditis elegans (PAR-4),
suggesting a conserved role thorough evolution. The gene was ini-
tially identiﬁed in C. elegans [15] and Xenopus [16], but it attracted
considerable interest when germline inactivating mutations of
LKB1 were linked to Peutz–Jeghers syndrome (PJS), a syndrome
characterized by benign gastrointestinal polyps and increased sus-
ceptibility to a large variety of malignancies [17]. The tumour sup-
pressor role of LKB1 has since been underscored by the observation
of LKB1 somatic mutations in sporadic lung cancer [18], and also
by the more recent suggestion that it may act as a major cervical
tumour suppressor [19].
2. LKB1 loss and human disease
2.1. Inherited Lkb1 loss and Peutz–Jeghers syndrome
The LKB1/STK11 gene was ﬁrst cloned as a result of a compara-
tive genomic hybridization analysis performed on patients suffer-
ing from Peutz–Jeghers syndrome (PJS) [17,20,21]. Initially,
chromosome 19p13.3 locus mutations were reported to be the pri-
mary cause of PJS [20], and following an intense analysis of this re-
gion the LKB1 gene was pinpointed [17,21]. Subsequently, the
majority of PJS cases have been conﬁrmed as being characterized
by germline LKB1 mutations [22,23].lsevier B.V. All rights reserved.
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ized by multiple polyps in the gastrointestinal tract that develop
predominately in the small intestine, but also with fewer lesions
arising in the large intestine and stomach [17,24–27]. The most
distinguishing manifestation of PJS is mucocutaneous pigmenta-
tion, which is present in childhood but can disappear later. These
melanin pigment spots can affect lips, the buccal mucosa as well
as the face, forearms, anus, ﬁngers, toes and intestinal mucosa
[28]. PJS gastrointestinal polyps develop early in life and can lead
to chronic bleeding, abdominal pain and recurrent bowel obstruc-
tions [29]. The polyps have distinct histopathological characteris-
tics, usually being on stalk-like growths; with the intestinal
crypts and gastric pits/glands often elongated but with relatively
normal differentiation. The tumour mucosa is normally built
around a core of arborising muscle extending from the stalk base
to the tumour fronds [30].
In terms of the cellular mechanism driving polyp formation, it
has been suggested that this occurs due to an expansion of the pro-
genitor cell compartment and a disruption of a balance between
symmetrical and asymmetrical stem cell division leading to muco-
sal prolapse [30,31]. Indeed, polyps may actually reﬂect mucosal
prolapse rather than true hamartoma [30], with the polyps having
relatively little malignant potential and PJS malignancy being dri-
ven out of overall mucosal instability rather than simple polyp pro-
gression. In this context, polyp removal may not lead to the
reduction in the risk of cancer [30,31].
Although the intestinal polyps appear benign, PJS patients are
however at risk of developing malignant tumours after the age of
30, and by the age of 65 the frequency of malignant transformation
is 93% [27,32]. The most common PJS associated cancers are gas-
trointestinal in origin: gastric, small intestinal, colorectal, pancre-
atic and sometimes esophageal [28,29]. The risk of breast cancer
in women is also elevated, being 8% at age 40 and it reaching
45% at the age of 70 [27]. Tumours can also develop in the ovary,
lung, uterus, cervix, testis, sex cord and in Sertoli cells [28,33–40].
2.2. Somatic inactivation of LKB1 and human tumourigenesis
PJS can develop not only as a result of germ-line inactivation,
but also can arise from somatic mutations [41]. However, LKB1
mutation has not been yet been reported as a frequent phenome-
non in colorectal cancer [42]. Screening for somatic mutational
inactivation of LKB1 in human breast and testicular cancers also
failed to reveal high frequencies of mutation [42–44], although
analyses of sporadic pancreatic and biliary adenocarcinomas has
shown some elevation in mutation frequency, with 4–6% of them
being associated with LKB1 sporadic mutation [45].
LKB1 has recently been shown to be frequently mutated in lung
cancer (>30% [46,47]) suggesting that the mutation frequency in
the original study [43] may have been underestimated. Indeed,
more sensitive methods of detecting LKB1 mutations, such as the
use of multiplex ligation-dependent probe ampliﬁcation (MLPA),
have revealed higher mutation frequencies than previously re-
ported. Thus, the LKB1 mutation frequency in cervical cancer has
recently been reported to be as high as 20%, considerably elevated
compared to previous estimations. Furthermore, these studies
have suggested that LKB1 mutation is associated with accelerated
disease progression [19]. The authors of this report also found that
the majority cervical cancer cell lines, including HeLa, contain Lkb1
biallelic mutations [19]. The absence of LKB1 protein in HeLa cells
had been previously reported [48] but it was attributed to pro-
moter methylation rather than mutation [49].
Despite the situation in HeLa cells, epigenetic suppression of
LKB1 does appear to be an important mechanism of LKB1 inactiva-
tion, with LKB1 promoter hypermethylation present in 45% of pap-
illary breast carcinomas and 18% of hamartomatous polyp lesions[49]. These observations suggest that the rate of epigenetic sup-
pression may be higher than thought in other tumour types. For
example, downregulation of LKB1 expression in endometrial can-
cer is signiﬁcantly more common according to tissue microarray
than would be predicted frommutation frequency, implicating epi-
genetic suppression [50].
2.3. Lung cancer
The most common cause of tumour-related death worldwide
is lung cancer. It is also the most actively studied cancer in rela-
tion to LKB1 inactivation apart from PJS. When chromosomal
alterations were analyzed in lung tumours, a 19p allelic imbal-
ance was identiﬁed as a frequent event in tobacco-exposed pa-
tients [51]. Subsequent genetic analysis of primary lung
adenocarcinoma samples revealed that a third of them harboured
LKB1 mutations, and that all of these were somatic [18]. These
ﬁndings were further supported when a large number of lung
cancer cell lines were screened for both genetic alterations and
changes in LKB1 expression [46,47,52,53]. LKB1 deﬁciency was
shown to be particularly common in non-small cell lung cancers,
(NSCLCs) and primarily affected males and smokers. LKB1 muta-
tions were also found to be signiﬁcantly more frequent in poorly
differentiated adenocarcinomas than in those with higher degrees
of differentiation [46,52].
Another characteristic feature of LKB1-deﬁcient human lung
cancers is that they have been observed concurrently with KRAS
mutations [18,46]. Further evidence of functionality for K-Ras in
mediating tumourigenesis comes from the observation that tu-
mours characterized by concomitant LKB1 and K-Ras mutations
exhibit increased sensitivity to both MAPK and mTOR inhibition
[54]. Although male PJS patients do show elevated levels of lung
cancer compared with the general population, this incidence is
not as high as for other types of PJS-associated cancer [27,28],
suggesting that multiple events including K-Ras activation are
necessary to drive LKB1 associated lung tumourigenesis. This
requirement for other interacting mutations is further under-
lined by the genetic variability observed between Caucasian
and Asian patients, with the LKB1 mutation rate being far
higher in NSCLC tumours and cell lines derived from the pa-
tients of Caucasian origin then in the patients of Asian origin
[46,52,55,56].3. Animal models of LKB1 loss
The importance of LKB1 in human disease was originally high-
lighted when its loss of function was linked with PJS development
[17]. Disease suppression by LKB1 has now been studied in a range
of different tumour types as outlined above and also in other dis-
ease settings, such as metabolic syndrome and type II diabetes
[57–59]. To better understand the relationship between LKB1 and
these different pathologies, a range of model organisms have been
utilized including yeast, worms, Drosophila, frogs and mice [60–
67]. It is becoming obvious that the role played by LKB1 is complex,
impacting upon a wide range of signalling pathways and producing
highly tissue-speciﬁc effects. Thus, different models of Lkb1-
deﬁcient cancer implicate different mechanisms. For example, gas-
trointestinal polyposis in Lkb1-deﬁcient mice affects both the
mTOR and TGFb pathways [68–69], whilst in contrast endometrial
cancer shows AMPK downregulation without overt changes in
mTOR [51]. In terms of pathway interactions there are also very
clear differences, such as p21/p53 pathway downregulation in pan-
creatic cancer driven by Lkb1 haploinsufﬁciency [70], the interac-
tion with Src/Fak in lung cancer [71] compared to the
involvement of the Rb pathway in skin cancer [72].
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between mTOR and TGFb
Whereas constitutive Lkb1/ knockout mice are embryonic
lethal [64], heterozygous Lkb1+/ mice created in different labora-
tories have been shown to be viable and prone to severe polyposis
at around 8 months of age [65–67]. Gastrointestinal hamartomas
of Lkb1 heterozygous mice share similar histological features com-
pared to human PJS polyps and it has also been demonstrated that
biallelic Lkb1 inactivation is not necessary for polyp development.
[65–67,73,74]. At the same time, histological examination of pol-
yps failed to ﬁnd dysplastic or adenomatous changes suggesting
that the polyps themselves do not progress [66], which is again
reﬂective of the human situation.
One of the most important unresolved issues is the precise
mechanism that drives Lkb1-deﬁcient polyp development. mTOR
pathway deregulation is an obvious candidate since Lkb1 nega-
tively regulates mTOR via AMPK/TSC2 [75,76]. Consistent with this,
Lkb1-deﬁcient tumours show hyperactivation of mTORC1, with
rapamycin treatment dramatically suppressing preexisting polyps
and also downregulating hypoxia-induced factor HIF-1a and its
targets [69,75]. Furthermore, activators of AMPK such as metfor-
min, phenformin or A-769662 have all been shown to signiﬁcantly
delay tumour onset in mice with reduced levels of Lkb1 and PTEN,
again mechanistically implicating mTOR. [77].
Alternatively, loss of TGFb-mediated communication between
smooth muscle cells and the epithelium may drive intestinal dis-
ease [68]. Defects in mesenchyme-originated TGFb production
leading to epithelial alterations have been documented before
[78], and the control of TGFb production by Lkb1 may also explain
its tumour suppressor function. Thus, when Lkb1 was conditionally
removed from smooth muscle cells using TagIn (SM22) driven Cre
recombinase, the mice developed multiple gastrointestinal tu-
mours [68] and the resulting phenotype was reminiscent of consti-
tutive Lkb1 heterozygous mice [65–67]. Lkb1 deﬁciency targeted
to the mesenchyme resulted in a drop in TGFb production and sub-
sequent decrease in phospho-SMAD2 in the epithelium [68]. The
resulting tumours showed hyperplasic epithelium and a strong
stromal component and smooth muscle core (identical to the pol-
yps arising in Lkb1+/ mice). These results argue for a primary role
for the mesenchymal compartment in this mouse model of
Peutz–Jeghers syndrome (PJS) [68].
The exact mechanism by which Lkb1 regulates TGFb production
remains unknown, but it is plausible to speculate that it may arise
as a consequence of abnormal cell polarity and differentiation lead-
ing to defects in TGFb ligand secretion and maturation. For exam-
ple, Lkb1 deﬁciency causes defective myogenic differentiation with
decreased smooth muscle actin expression and defective actin ﬁ-
bers [79]. Furthermore, several Lkb1-deﬁcient models have shown
defects in cytoskeleton and polarity [7,80], phenotypes which may
well also underlie perturbation of TGFb production.
The link between the PI3K/Akt/mTOR pathway and TGFb signal-
ling is particularly interesting given that defects in either pathway
may lead to similar hamartomatous polyposis. Thus, PJS, Tuberous
Sclerosis Complex and Cowden Syndrome are respectively caused
by deﬁciencies in LKB1, TSC1/TSC2 and PTEN [17,81,82]. Given
the above discussion of the role of TGFb in polyp formation, it is
also notable that Juvenile Polyposis is largely associated with
SMAD4 loss [83]. It is however not yet clear whether misregulation
of the mTOR and TGFb pathways represents completely separate
events or if they are affecting each other in some way. For example,
it appears that Lkb1-mediated TGFb ligand secretion is not con-
trolled by mTOR, since the loss of TGFb production in Lkb1-
deﬁcient cells was not reverted by rapamycin treatment, nor were
overt changes observed in either AMPK or mTOR expression [68].
At the same time, it would be still interesting to assess the effectsof rapamycin on tumour development in the SM22-Cre model. By
contrast, the PI3K/Akt/mTOR has been implicated in events down-
stream of the TGFb receptor. Thus, TSC2 can interact with the
SMAD proteins and colocalize to the nucleus following stimulation
by TGFb and this cooperation can suppress cell proliferation by
activating both p21 and p27 expression [84]. This is an area that
clearly needs further examination, especially as the appropriate
genetic tools are now available to probe this interaction.
3.2. Lkb1 deletion disrupts cell polarity, cell adhesion and can lead to
abnormal differentiation and metastasis
Lkb1 is a key player in establishing the correct polarity in C. ele-
gans [15,85] and in Drosophila [62,86]. Lkb1 mutations in Dro-
sophila abrogate proper localisation of proteins and affect spindle
formation [87]. In mammalian models, Lkb1 loss often leads to
combined defects in cell adhesion, polarity and motility creating
a potential for tumourigenesis and metastasis [71,88].
Lung cancer is the tumour type in which the role of Lkb1 in
migration, adhesion and polarity is perhaps been most intensively
studied, given the clear importance of LKB1 somatic mutations in
human lung [18,89]. Given the coincidence of LKB1 mutations
and K-Ras mutations in human tumourigenesis mentioned above,
this potential interaction has now been modelled in the mouse,
with combined mutation resulting in a much stronger synergistic
effect than concomitant mutations of K-Ras with other tumour
suppressors such as p53, Ink4a/Arf or p16 [57]. Thus, mouse sur-
vival was greatly reduced, with animals developing lung tumours
belonging to a broad histological spectrum and with a high ability
to invade and metastasise [57]. The same research group also con-
centrated on expression and phosphoproteomic changes occurring
in these K-Ras mutant tumours with or without Lkb1 as well as
with or without metastasis [71]. They found several signatures
speciﬁc for epithelial-mesenchymal transition such as Snail1,
Twist1 and also SRC and FAK activation suggesting increased cellu-
lar migration as well as impaired cell adhesion [71]. The authors
also showed that Lkb1 loss can lead to an addiction to SRC and
FAK signalling in both cell migration and adhesion. Thus in this set-
ting Lkb1 deletion not only relieves mTOR signalling but also acti-
vates the SRC/FAK axis, so linking metastasis with tumour cell
growth [71].
Recent studies have suggested that LKB1may affect cell motility
via several different mechanisms. The LKB1/AMPK axis has been
shown to regulate tight junction assembly and cell polarity
[90,91], it is able to suppress tubulin polymerization via activating
microtubule-associated protein (MARK) signalling [92], and it can
also phosphorylate PAK1, a key protein controlling cell motility
[93]. The interaction of LKB1with PAK1 is crucial to cell polarization
andmotility,with co-localization of LKB1 and PAK1 at the actin scaf-
fold of the leading edge of a cell leading to Lkb1-mediatedphosphor-
ylationof PAK1and subsequent recruitment and activationof cdc42.
Normal functioning of these processes appear to be required for cell
polarity events, such as lamellipodia formation and Golgi reorienta-
tion, with LKB1 appearing to be a dynamic, actin-associated protein,
the depletion of which results in classic cell polarity defects, such as
aberrant morphology and organelle positioning [88].
Interesting results were obtained using 3D organotypic mam-
mary acinar structures [94]. Mammary epithelial cells can develop
poorly differentiated cysts if cultured in collagen matrix but they
are able to form polarized epithelial structures if cultured in Matri-
gel instead. This organized epithelial structure can prevent prolif-
eration caused by c-Myc activation. When the tissue architecture
and polarity was disrupted by LKB1 loss, c-Myc driven proliferation
in acinar structures was reinitiated. The disruption was mTOR-
independent and rapamycin did not inhibit the reinitiation of the
cell cycle by c-Myc [94].
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ing anoikis. Cell that lose anchorage to their native matrix often
undergo this detachment-induced cell death [95], with clear impli-
cations for this process in tumour invasion and metastasis. LKB1
has been shown to participate in this process via the phosphoryla-
tion of SIK1 kinase, a role which has been demonstrated to be
important in the p53-dependent suppression of anchorage-
independent growth [95].
Lkb1 deﬁciency has also been shown to cause signiﬁcant polar-
ity defects in the pancreas, mostly attributed to inactivation of the
downstream AMPK/MARK/SAD family kinases. These defects in-
cluded cytoskeletal abnormalities, loss of acinar cell polarity and
tight junctions, which are considered to contribute to the develop-
ment of pancreatic serous cystadenomas, a tumour type associated
with PJS [7]. The interaction of Lkb1 with Par1b/MARK2 also seems
to be crucial in maintaining beta cell polarity and intracellular cilia
positioning as evidenced from the phenotype of pancreatic condi-
tional deletion using Pdx1-Cre [96].
The role of LKB1 in polarity has been reported to be crucial in
axon initiation and differentiation in cultured hippocampal neu-
rons [97]. In this context, the LKB1/STRAD pair mediates the devel-
opment of undifferentiated neuritis, with local accumulation of
LKB1/STRAD considered to bias growth capacity towards one neu-
rite and that this process can promote axon initiation [97]. These
ﬁndings were complimented when LKB1 expression was selec-
tively disrupted in the murine neocortex. This prevented axon for-
mation without changes in neuronal migration and cortical
layering. The authors proposed that in this setting Lkb1, together
with downstream SAD-A and SAD-B kinases, is indispensable for
axon formation in the neocortex [6]. Similarly, Lkb1 has been re-
ported to specify axon and dendrite identity, as deletion of Lkb1
in migrating immature neurons disrupted centrosome positioning
as well as axonal and dendritic polarity, ultimately resulting in im-
paired neuronal migration and differentiation [98].
We have recently shown that loss of Lkb1 can also affect intes-
tinal differentiation. Selective removal of Lkb1 from the mouse
intestinal epithelium leads to the expansion of secretory cell lin-
eages together with changes in their differentiation [99]. This ex-
panded population retains features of both Goblet and Paneth
cells, the two major secretory cell types within the intestine, sug-
gesting a failure of normal differentiation of these lineages. This
phenotype is characterized by deregulated Notch signalling, possi-
bly due to reduced Delta ligand levels in the secretory cells, which
may in turn be due to greatly diminished MARK kinase phosphor-
ylation [99].
Defects in cell polarity, adhesion and function have been in a
spectrum of other Lkb1-deﬁcient tissues. For example, we have
also shown that Lkb1 deletion in the prostate leads to loss of tight
junctions and initiates tumourigenesis [100]. Furthermore, others
have shown that the Lkb1/AMPK axis is important in hepatocyte
polarity and canalicular network formation in bile ducts [101].
3.3. Lkb1 controls mouse angiogenesis
Constitutive homozygous ablation of Lkb1 causes lethality at
embryonic day 11 [64]. Lkb1 null embryos several angiogenic phe-
notypes, including thin and discontinuous aorta, rudimentary yolk
sac vasculature and little or no invasion of allantoic blood vessels
into the placenta [64]. Similar results were obtained when Lkb1
was deleted conditionally using Mox2-Cre recombinase which
spared Lkb1 in trophoblasts but caused deletion in the embryo,
allantois and yolk sac mesoderm [102]. To determine whether
lethality arises as a consequence of a cell-speciﬁc role of Lkb1 in
the vascular system, mice have been generated using the Tie1-
Cre transgene to drive endothelium-speciﬁc Lkb1 deletion [102].
In this model, deletion of Lkb1 in the endothelial lining of bloodvessels reduced TGFb production and resulted in fragile and dis-
torted vessels characterized by loss of the supporting vascular
smooth muscle cells necessary for stabilization and maturation.
This phenotype therefore largely mimicked that seen in the consti-
tutive knockouts [64]. It was also similar to the phenotypes ob-
served following TGFb pathway deregulation, such as that seen
after smooth muscle speciﬁc deletion of TGFbRII [103]. Consistent
with these similarities, Lkb1-deﬁcient embryos showed a clear
downregulation of the TGFb pathway, with levels of phosphory-
lated SMAD2 signiﬁcantly lower both in Lkb1-deﬁcient yolk sac
and in mesenchymal cells [102]. These observations suggest that
the endothelial cells are relying on TGFb-based communication be-
tween endothelium and smooth muscle to recruit smooth muscle
cells into the newly formed blood vessels. The role of Lkb1 in this
process appears to be in regulating TGFb availability to the nearby
smooth muscle and mesenchymal cells, such that deﬁciency of
Lkb1 results in the incomplete coverage of maturing vessels with
smooth muscle cells [102].
Lkb1 has also been studied in relation to the revascularization
response to ischemia [104]. The approach used here was to use
Tie2-Cre driven deletion of Lkb1, again within endothelium.
Homozygous deletion resulted in embryonic lethality, however
heterozygous deletion resulted in normal capillary density if
unchallenged, but a greatly reduced response to ischemia when as-
sessed at the microcirculatory level. In terms of mechanism, these
effects appear to be mediated through the interaction with AMPK,
with the speculation that stress, nutritional deprivation and hy-
poxia activate AMPK signalling in endothelial cells, such that the
Lkb1-AMPK axis then stimulates a pro-angiogenic response.
3.4. Lkb1 and AMPK inﬂuence feeding behavior, adiposity and nutrient
rationing
Food shortages or stressful environmental conditions often af-
fect animal development, metabolism and behavior. In mammals,
the hypothalamus plays a key role in appetite control and subse-
quent behavioral strategy by integrating satiety signals coming
from both adipose tissue and the gastrointestinal tract [105]. Both
AMPK and Lkb1 play prominent roles in the hypothalamus, inﬂu-
encing feeding behavior and metabolism in response to these sig-
nals [106]. In support of this, Lkb1 deletion using the RIP2.Cre
transgene, which is active in both pancreas and hypothalamus,
has been shown to reduce food intake and weight gain [107]. Sim-
ilarly, activation of AMPK in rats can increase food intake [108],
and AMPKb1-deﬁcient mice are characterized by both reduced
body weight and appetite [109]. However, this regulation is clearly
complex, as constitutive knockouts of either AMPKa1 or AMPKa2
show no change in body weight or appetite [110], Furthermore,
AMPKa2 deletion in different types of neurons has been shown
to lead to opposing effects on body weight, possibly reﬂecting dif-
ferences between hormone sensing cells and glucose sensing ones
[111].
Clearly, Lkb1/AMPK signalling is important in feeding/satiety
and this may have potential ramiﬁcations for obesity research. In
this context, the interaction of Lkb1 with Fyn tyrosine kinase is
of particular interest, as mice bearing a knockout of Fyn tyrosine
kinase have been reported to be leaner with increased activation
of AMPK in the adipose tissue [112]. Given that Fyn phosphorylates
Lkb1 at tyrosine residues 261 and 365 with the consequence that
Lkb1 is retained in the nucleus, then inhibition of Fyn should lead
to Lkb1 cytoplasmic export and subsequent activation of AMPK-
driven energy expenditure with the ultimate result of a reduction
in fat reserves [113].
In contrast to mice, the Lkb1/AMPK pair in the nematode
C. elegans actually protects its energy reserves during the dauer
stage [61]. C. elegans is known to enter dauer diapause in harsh
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and carbohydrate reserves. After entering diapause they stop feed-
ing and ration their nutrient storage, with a resultant increased
lifespan [114]. AMPK appears a critical regulator of this process,
as deletion of the a2 catalytic subunit of AMPK leads to more than
a threefold reduction in animal survival. Consistent with this, dou-
ble knockouts of the b1 and b2 subunits of AMPK as well as of the
Lkb1/STRAD pair both result in similar decreases in longevity [61].
3.5. Lkb1 loss in liver affects whole body glucose metabolism in a
diametrically opposed fashion to the loss of pancreatic Lkb1
Type 2 diabetes is commonly associated with high blood glu-
cose combined with insulin resistance. High blood glucose is usu-
ally the result of excessive glucose production in the liver
(gluconeogenesis). Lkb1 has been implicated in these processes
as liver-speciﬁc deletion leads to increase in both gluconeogenesis
and lipogenesis, both of which are signiﬁcant energy consuming
processes [115]. The mechanism underlying this role appears to
be the phosphorylation of CREB-regulated transcription coactiva-
tor 2 (CRTC2 or TORC2) by Lkb1/AMPK. The consequence of such
phosphorylation is relocation to the cytoplasm and consequent
prevention of gluconeogenic program induction [115].
Metformin is the key anti-gluconeogenic drug used for the
treatment of diabetes, and it has been suggested that the Lkb1/
AMPK axis is the main executor of its action [115]. However, it
was recently been shown that metformin can also suppress gluco-
neogenesis directly, bypassing Lkb1/AMPK [116]. Metformin ac-
tions may indeed be wider that AMPK activation as the principal
function of the drug is to inhibit ATP production by complex I of
mitochondrial oxidative phosphorylation, so creating a AMP/ATP
ratio, which in turn not only acts on the Lkb1/AMPK axis but also
directly affects gluconeogenesis and glycolysis via the allosteric
inhibition of key enzymes [117].
Remarkably, whereas liver-speciﬁc Lkb1 deletion leads to high
blood glucose levels due to unrestricted gluconeogenesis, the dele-
tion of Lkb1 in the pancreas actually enhances glycemic control
[96,101,107]. Thus, mice deﬁcient for pancreatic Lkb1 (Pdx1-Cre)
had normal fed and fasting glucose levels but they displayed a fas-
ter and more efﬁcient response to glucose than wild-type animals
[96,101,107]. The mechanism underpinning this remains largely
unclear, but may simply reﬂect elevated serum insulin levels as a
consequence of enlarged pancreatic b-cells in the absence of
Lkb1 [96,101,107].
3.6. Lkb1 loss and cell survival
The role of Lkb1 role in the regulation of apoptosis appears to be
highly tissue speciﬁc. Thus, depending on a cell type, Lkb1 loss can
either compromise apoptosis or enhance it. The pro-apoptotic role
of Lkb1, which might be considered consistent with its role as a tu-
mour suppressor, has been relatively well described. Thus, Lkb1
has been shown to be involved in TRAIL-mediated apoptosis in
osteosarcomas [118]. As already discussed it controls p53-depen-
dent anoikis [95] as well as p53-dependent apoptosis [119], the
latter via translocating Lkb1 into the mitochondria [119].
At the same time Lkb1 deletion can compromise survival of
those cells which have tight energy rationing, such as lymphocytes.
The normal immune response often requires bursts in lymphocyte
proliferation and this is obviously an energy demanding process.
Given the role of Lkb1 in regulating energy production/demands,
Lkb1 status would be predicted to be critical to this tissue type. Re-
cently, two separate groups have described Lkb1 loss in T-cells.
They both used Cre-recombinase with expression driven by the
lymphocyte protein tyrosine kinase (Lck) promoter to generate
LckCre+Lkb1ﬂ/ﬂ mice [120–122]. Although the mice were viable,they had reduced numbers of thymocytes, substantial amounts of
T-cell death and very small thymi with abnormal tissue architec-
ture [120,121]. Analysis of the T-cell populations in these mice re-
vealed a reduction in double positive mature thymocytes (with
both CD4+ and CD8+), but higher levels of immature double nega-
tive T-cell progenitors, which were largely arrested at the CD4
CD8 CD44 CD25+ (DN3) stage. As described above, T-cell survival
was compromised by deﬁciency of Lkb1, however the cells could
be rescued by either ectopic expression of Bcl-XL or constitutively
active AMPK expression, again underscoring the anti-apoptotic
role of the Lkb1/AMPK pair in this setting [120].
One view of the Lkb1/AMPK pair is that they function as part a
cellular mechanism preventing energy addicted cells from entering
apoptosis triggered by an elevated AMP/ATP ratio. Indeed, mimick-
ing high AMP/ATP ratios by AICAR treatment can induce apoptosis
in lymphocytes, although neither phenformin nor the direct AMPK
activator A-769662 have the same effect [123]. Moreover, metfor-
min, a drug known to activate AMPK/Lkb1 [114] can also promote
mature T-cell survival [124]. It is tempting to suggest that in en-
ergy-rich cells, Lkb1 loss permits higher proliferation rates and
ultimately tumourigenesis, however such a mechanism would
drive the expansion of cells which would be much more vulnerable
to death in a context of falling ATP levels due to Lkb1 dysfunction.
It is perhaps more tempting to speculate that Lkb1 can allow adap-
tation to metabolic stress [125] and its deletion may selectively
eliminate some vulnerable cell lineages in favour of more stress
resistant ones.
3.7. Lkb1 deﬁciency causes cardiac hypertrophy and affects skeletal
muscle physiology
Cardiac tissue is capable of adaptive growth in response to var-
ious different stimuli including pregnancy or exercise [126]. This
adaptation is underpinned by increased protein synthesis, with
mTOR playing a key role in this process [127]. As in other tissues,
Lkb1 has been suggested to regulate mTOR [128]. To speciﬁcally
examine its role in this tissue, mice have been generated with a
cardiac-speciﬁc Lkb1 deletion driven by a aMHC-Cre transgene.
These mice exhibited severe atrial and ventricular hypertrophy,
ﬁbrillation changes and increased mortality [129]. The hypertro-
phic effect in these phenotypes appears to be due to abnormal
mTOR activity, as shown through in vitro experiments with the
mTOR inhibitor rapamycin and constitutively active AMPK [129].
Notably, regulation of protein synthesis through mTOR is not the
only cardiac cellular mechanism inﬂuenced by Lkb1, as the Lkb1/
AMPK pair is also responsible for the increase in long chain fatty
acids and glucose uptake (the main fuel for cardiac ATP produc-
tion) in response to contraction or exposure to ATP/AMP ratio low-
ering agents such as AICAR [130].
A slightly different phenotype has been reported from mice in
which Lkb1 has been deleted in both cardiac and skeletal muscle
using a muscle creatine kinase promoter driven Cre (MCK-Cre).
Although these mice did not develop a severe cardiac phenotype,
cardiac function was again impaired and mTOR/p70S6 signalling
increased due to impaired AMPK phosphorylation [131,132].
Taken together, these studies support a potent role for Lkb1 in
cardiac muscle regulation, although there are clear differences
in phenotype which may reﬂect cell type speciﬁcity or simply
the extent of recombination delivered by the different cre trans-
genes. Somewhat similar phenotypes have also been observed in
Lkb1 deﬁcient skeletal muscle, with reduced AMPK activation
and an increased AMP/ATP ratio [133]. Although Lkb1-deﬁcient
muscle showed increases in glucose uptake and improved glu-
cose tolerance [134], they had a deﬁcient contraction-stimulated
glucose uptake [133] as well as decreased voluntary running abil-
ity [135].
Fig. 1. A simpliﬁed scheme of pleiotropic effects of Lkb1 activity: Lkb1 phosphorylates a family of kinases regulating diverse intracellular and extracellular biological
processes. Tissue-speciﬁc Lkb1 loss can affect the whole range of different signalling pathways.
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Lkb1 was initially discovered because of its role as a tumour
suppressor and it is mutated in a number of cancers (PJS, lung
and cervical cancer) but it is becoming apparent that Lkb1 has a
wide range of biological roles that reach far beyond that. This ser-
ine-threonine kinase serves as a master kinase and its loss can af-
fect a variety of biological processes including energy metabolism,
cell structure, migration, adhesion and polarity (Fig. 1). Recent
‘‘in vivo’’ data obtained on animal models suggested that Lkb1 is
often responsible for coupling cell growth, structure and survival
to nutrient conditions and energy rationing. Lkb1 deletion can
selectively eliminate some cell types and favour proliferation of
others. In vivo effects of Lkb1 loss seem to be highly complex
and they depend on a number of other biochemical settings. We
cannot underestimate the importance of animal models providing
us with an excellent opportunity to study tissue-speciﬁc Lkb1 loss
and ﬁnd better therapeutic approaches for a variety of pathological
conditions.References
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